Clinical trials: Advanced Malignant Glioma, open to volunteers
Cytokine-Induced Killer Cells, Advanced Milignant Gliomas
Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas
The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Advanced Malignant Gliomas.
- Trial name
- NCT02496988
- Testing
- Temozolomide, CIK
- Volunteers
- 120 people
- Sponsor
- The First People's Hospital of Changzhou
Glioma
Telehealth Visits to Discuss Advanced Directives for Patients Newly Diagnosed With High Grade Glioma
High grade gliomas (HGGs) are rapidly progressive brain tumors resulting in death for most patients between 6 months and 2 years after diagnosis.
- Trial name
- NCT04543201
- Testing
- Early START visit using checklist over telephone or zoom
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Rochester
Brain Tumor, Recurrent, Cancer, Advanced
Azoles Targeting Recurrent High Grade Gliomas
High-grade gliomas are the most common and aggressive type of brain cancer. Scientists don't fully understand how they grow and spread, and treatments haven't improved much in recent years.
- Conditions
- Brain Tumor, Recurrent, Cancer, Advanced, Glioma of Brain
- Trial name
- NCT03763396
- Testing
- Ketoconazole (KCZ), Posaconazole (PCZ)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Malignant Glioma
Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma
This study examines whether repeated magnetic resonance imaging (MRI)s scan helps identify changes in the tumor during radiation and chemotherapy treatment in patients with high grade glioma.
- Trial name
- NCT04771806
- Testing
- Magnetic Resonance Imaging, Neurocognitive Assessment, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Tumor, Brain Metastases
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in patients with Advanced Brain Cancer including Gliomas and…
- Conditions
- Brain Tumor, Brain Metastases, Brain Cancer, Glioma
- Trial name
- BAH2472 (NCT06640582)
- Testing
- Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Advanced Malignant Solid Neoplasm, RAS Mutation
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed…
- Conditions
- Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer
- Trial name
- NCT04678648
- Testing
- RSC-1255 Dose Escalation, RSC-1255 Dose Expansion
- Where
- 3 sites in United States
- Volunteers
- 134 people
- Sponsor
- RasCal Therapeutics, Inc.
High-grade Glioma, Solid Tumor, Unspecified, Child
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
An open label, non-randomized study in pediatric patients with advanced high-grade gliomas and other solid tumors. The study will be performed in two phases: a dose escalation phase in up to 18 patients following a standard "3+3"…
- Trial name
- NCT04299191
- Testing
- LAM561
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Laminar Pharmaceuticals
Glioblastoma, Astrocytoma, IDH-Mutant, Grade 4
Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques
Rationale: Patients with IDH-wildtype glioblastoma or grade IV IDH-mutant astrocytoma have a very poor prognosis despite standard treatment consisting of surgery, radiotherapy, and chemotherapy.
- Trial name
- NEXTFRONTIER (NCT06623565)
- Testing
- Multimodal image-guided resection
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Amsterdam UMC, location VUmc
Solid Tumor, Solid Carcinoma
Imaging of Solid Tumors Using 18F-TRX
This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan.
- Conditions
- Solid Tumor, Solid Carcinoma, Castration-Resistant Prostate Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma
- Trial name
- NCT06942104
- Testing
- 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Rahul Aggarwal
Melanoma, Non Small Cell Lung Cancer
Dabrafenib and/or Trametinib Rollover Study
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
- Trial name
- NCT03340506
- Testing
- dabrafenib, trametinib
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Brain Cancer, Glioma
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
The researchers think that the use of advanced MR imaging may help people with this disease, because it may better predict areas within a malignant glioma (brain tumor) that are at a high risk of recurring.
- Trial name
- NCT00870129
- Testing
- MRI and advanced MRI sequences
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Memorial Sloan Kettering Cancer Center